DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* HYBRIGENICS *


 

1998 - IDF
Paris
www.hybrigenics-services.com

 

Discovery, Drugs
(also, Services, Research)
Key words: Protein-protein interaction, Cancer, Inecalcitol, D-vitamin, Protease inhibitor, Protein-interactions maps (PIMs), Ubiquitin
Mission: to develop internal R&D programs on innovative target and therapeutics against cancer and to market proprietary high throughput technology and bioinformatics platforms focused on identification, validation and inhibition of protein interactions
Clients: Prescribers
contact@hybrigenics.com

Age: 19 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Academic |
Managing Dir.-CEO: Delansorne (Rémi) [born 1959, Vet.D., Ph.D., ex-Theramex (Merck KgAa)]
Oper.Dir.-COO: Formstecher (Etienne) [Polytechnique, Ph.D., also deputy CEO]
Tech.Dir.: Rain (Jean-Christophe) [Ph.D. Molecular Genetics, co-founder, also deputy CEO]
I.T.Dir.-CIO: Collura (Vincent) [Ph.D. structural bioinformatics]
Financers (Hist.): Medicis, Rendex, Sofindev, IMH, Lombard Odier, Alafi Capital, Life Science Partners, Banexi V.P., C.F. Edmond de Rothschild, Public
note : in September 2012, the company changes its URL from www.hybrigenics.com to www.hybrigenics-services.com

Turnover (M€) : 2.28 (2010), 4.17 (2009), 3.64 (2008)
Total funding (M€) : n.a.
Last funding (M€) : 2.7
Focus : Cancers
Position : Preclin
Company confirm : none

 

History
DATEMILESTONETYPETIME
2010 .09 Partnering research agreement with L'Oréal on protein interactions stydies beyond classical Yeast Two-Hybrid technology R&D [12 years]
2010 .09 Clinical trial (phase IIa) for inecalcitol (promising results) CLIN [12 years]
2010 .07 Set-up of Hybrigenics Services, a subsidiary servicing company dedicated to subcontracting activities ORGC [12 years]
2009 .12 Financing : 2.7 M€ issued for private investors, i.e. 10.5% capital, for inecalcitol development costs (in complement to Yorkville) RFIN [11 years]
2009 .09 Financing : up to 5 M€ through privileged new shares to Yorkville, over 3 years RFIN [11 years]
2009 .09 Partnering research agreement with yeast two-hybrid contract of 1.5 M€, for services to an American multinational life sciences company during 3 years R&D [11 years]
2009 .05 Set-up of Hybrigenics Services, a subsidiary owned by Rémi Delansorne ORGC [11 years]
2009 .02 Financing : 0.4 M€ by E.U. to participate in Masterswitch European project and screen inhibitors of protein interaction in the field of chronic inflammatory diseases RFIN [11 years]
2008 .12 Patent : granted on protease inhibitors specific to ubiquitin (cancer) LEGAL [10 years]
2008 .09 Financing (no interest loan) : 1.4 M€, by OSEO, to support its ongoing clinical development program of inecalcitol in prostate cancer DEBT [10 years]
2007 .12 Listing on Alternext : 6.2 M€ PBO [9 years]
2005 .09 Nomination : Rémi Delansorne, as CEO (previously CSO since 2004), replacing Donny Strosberg ORGN [7 years]
2003 .05 Acquisition of Semaia (Holland), a biotech focused on oncology ACQ+ [5 years]
2002 .04 3rd round-financing : 16.8 M€, led by Life Science Partners, with Banexi V.P., C.F. Edmond de Rothschild, and previous shareholders RFINC [4 years]
2000 .10 2nd round-financing : 19.5 M€, led by Alafi Capital, Lombard Odier, Medicis, Rendex, Sofindev, and previous shareholders RFINB [2 years]
1999 .06 1st round-financing : 9.1 M€, led by Auriga Partners, IMH, HealthCap, and previous shareholders RFINA [1 year]
1998 .05 Seed financing : 1 M€, by Apax Partners, Altamir SFIN [0 year]
1998 .04 Licensing-in of any discovery by Institut Pasteur on protein-protein interaction, with right of first refusal and exclusivity LICIN [0 year]
1998 .01 Company founded by Prof. Arthur Donny Strosberg (CEO), Pierre Legrain, Jacques Camonis, and Richard Benarous ORGF [0 year]

Actualisation / Updating: 13-Nov-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende